ImmunOs Therapeutics is a clinical-stage biotechnology company.
Immunos Therapeutics has raised €92M across 3 funding rounds from 14 investors, most recently a Series C round in Sep 2024. Based in Schlieren, Switzerland; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2024-09-18 | Series C | €9.9M | BioMed Partners,Double Point Ventures,Existing investors,Gimv,Mission BioCapital,Pfizer Ventures | View deal → |
| 2022-06-07 | Series B | €68M | BioMed Partners,Fiscus Financial,Gimv,GL Capital,Lightspeed Venture Partners,Mission BioCapital+4 more | View deal → |
| 2019-10-01 | Series A | €14M | BioMedPartners,Pfizer Venture Investments | View deal → |
